Pediatrix Medical Group, Inc. (MD) Form 10-Q — Oct 29, 2026
Pediatrix Medical Group reported Q3 2026 net revenue of $501.4 million, up 1.7% year over year, with Adjusted EPS of $0.72 versus $0.67 in the prior-year quarter. GAAP net income fell to $47.0 million from $71.7 million, which included a $20.9 million net gain on divested businesses last year, and Adjusted EBITDA slipped to $85.5 million from $87.3 million on higher operating expenses. The company repurchased 5.9 million shares for $144.7 million during the first nine months of 2026, leaving $21.5 million remaining under its $250 million August 2025 authorization. Cash stood at $311.9 million, and the company says operations and cash on hand are sufficient for at least the next 12 months.
Key figures
- Eps
- 0.59
- Revenue
- 501374000
- Net Income
- 46991000
- Revenue Yoy
- 1.7% (Q3); 3.2% nine months
- Total Assets
- 2139420000
- Cash Position
- 311916000
- Shares Outstanding
- 78124716
- Dso
- 42.5
- Buyback 9m
- 5.9M shares for $144.7M
- Diluted eps 9m
- $1.43 vs $1.54 prior year
- Revolver available
- $450.0M
- Operating margin q3
- 13.0% vs 13.8% prior year
- Q3 2025 net revenue
- $492.9M
- Q3 2026 net revenue
- $501.4M
- Term a loan balance
- $178.1M
- Adjusted eps 9m 2026
- $1.78 vs $1.54 prior year
- Adjusted eps q3 2026
- $0.72 vs $0.67 prior year
- Term a loan maturity
- February 2027
- Notes 2030 outstanding
- $400.0M of 5.375% senior notes due 2030
- Operating cash flow 9m
- $114.5M vs $160.1M prior year
- Adjusted ebitda 9m 2026
- $220.1M vs $209.7M prior year
- Adjusted ebitda q3 2026
- $85.5M vs $87.3M prior year
- Buyback remaining aug 2025 program
- $21.5M
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.